Fri, Oct 24, 2014, 4:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • rbi504 rbi504 Jan 16, 2013 9:20 AM Flag

    Study Comparing AEZS-108 to Doxorubicin as a Second Line Therapy of Endometrial Cancer

     

    There is information about the upcoming study with AEZS 108 and Endometrial Cancer. The study lead investigator is Dr Miller @ UT Southwestern medical Center in Dallas, and Dr Gabra @ Imperial College in London. They have not started enrolling, but on the clinical Trial website, it states the study will start in March. There will be 500 patients in the study, and it will be open label. Lets hope for a favorable partnership that is comparable to Endocyte received with Merck last April.

    Sentiment: Strong Buy

    This topic is deleted.
 
AEZS
1.17+0.02(+1.74%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.